Clinical trial · Interventional
Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
A Pilot Feasibility Study of Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety of making and giving Epstein-Barr virus (EBV) immunotherapy products to subjects with nasopharyngeal carcinoma (NPC) associated with EBV that has come back or spread to other parts of the body. EBV immunotherapy product is made with white blood cells from the participants body that are collected intravenously. This EBV immunotherapy product may stop cancer cells from growing abnormally. EBV immunotherapy products have been used in several research studies for NPC. Information from these studies suggests the EBV immunotherapy products may stop the growth of NPC in some subjects.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Epstein-Barr virus-specific adoptive T-cells immunotherapy | Biological | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Biological/Vaccine
- description
- Epstein-Barr virus-specific adoptive T-cells immunotherapy given intravenously on Days 1 and 14
- interventionNames
- Biological: Epstein-Barr virus-specific adoptive T-cells immunotherapy
Primary outcomes (1)
- measure
- The feasibility and safety of generating and administrating and EBV-specific adoptive T cell in participants with incurable locoregional relapsed and/or distant metastatic EBV-associated NPC.
- timeFrame
- 2 years
Secondary outcomes (3)
- measure
- The ability to collect specimens and measure potential biologic correlate of response to therapy
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically or cytologically proven NPC of any WHO grade, associated with EBV documented by the presence of EBER by in situ hybridization in the tumor. This must be confirmed by pathology review at Brigham and Women's Hospital. * Incurable NPC as defined by: relapsed or progressive disease after initial treatment with no potentially curative option; NPC with metastasis * Recovery from toxicity from any prior NPC therapy to grade 1 or better (CTCACE v.3.0) * 18 years of age or older * Evaluable disease, according to RECIST * ECOG performance status of 0-1 * Adequate bone marrow, liver and renal function Exclusion Criteria: * Radiotherapy for primary NPC within 8 weeks of enrollment, or radiotherapy for any other reason within 6 weeks * Chemotherapy for NPC within 2 weeks of enrollment * Other cancer in the past 5 years, except for carcinoma in situ of the cervix or bladder, or non-melanomatous skin cancer * Uncontrolled central nervous system metastases * Acute hepatitis, known HIV, or other condition that requires immunosuppressive therapy, including current use of systemic corticosteroids * Autoimmune disease that is active and requires current therapy * Active, uncontrolled, serious infection * Incomplete healing from previous major surgery * Significant history of uncontrolled cardiac disease * Women who have a positive B-hCG test or are breastfeeding * Any concurrent chemotherapy or other concurrent investigational agent not part of this study
References
Publications (0)
Data not yet available